This is paralleled in the varying clinical profile, as sporadic AD patients may exhibit high or low Aβ1−42 burden, with or without the prevalence of Tau of Lewy body biomarkers, in the cerebrospinal fluid. This evidence concerns the gene MAPT and Alzheimer disease.